Welcome to our dedicated page for Amneal Pharmaceuticals SEC filings (Ticker: AMRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) files a range of documents with the U.S. Securities and Exchange Commission that provide detailed insight into its operations, capital structure, and governance. This page brings together those SEC filings and pairs them with AI-powered tools to help readers interpret the information more efficiently.
For Amneal, current reports on Form 8-K are a key source of timely disclosures. Recent 8-K filings describe quarterly financial results, including net revenue trends across the Affordable Medicines, Specialty, and AvKARE segments, as well as updates to full-year guidance. Other 8-Ks outline significant financing transactions, such as new seven-year term B loans, senior secured notes due 2032, and amendments to the company’s revolving credit agreement, along with details on collateral, covenants, and maturity profiles.
Filings also cover governance and stockholder matters. For example, Amneal has reported preliminary financial results, changes to board composition when designation rights shifted under a stockholders agreement, and the board’s decision to hold Say-on-Pay advisory votes on an annual basis following stockholder preferences expressed at an annual meeting.
On this page, users can access Amneal’s Forms 8-K and, through links to its broader filing history, locate annual reports on Form 10-K and quarterly reports on Form 10-Q. These longer-form filings typically include segment discussions for Affordable Medicines, Specialty, and AvKARE, risk factor summaries, and explanations of non-GAAP measures such as adjusted EBITDA and adjusted diluted EPS referenced in earnings releases.
AI features on the platform provide summaries and highlights of lengthy filings, helping readers identify key topics such as segment performance, debt structure, covenant changes, and governance decisions without reading every line. Users interested in AMRX can use this page to monitor new filings as they appear on EDGAR, review historical disclosures, and better understand how regulatory documents reflect Amneal’s evolving business and capital structure.
Amneal Pharmaceuticals insider sale: Jason B. Daly, EVP and Chief Legal Officer, sold 22,000 shares of Class A common stock at a weighted average price of $9.05 per share on 08/12/2025. After the reported sale, Daly directly holds 10,606 shares. The filing notes the sale was executed in multiple transactions with prices ranging from $9.01 to $9.13 and that full per-trade details will be provided to the company or the SEC on request. The Form 4 was submitted by an attorney-in-fact on behalf of the reporting person.
Andrew S. Boyer, Executive Vice President of Amneal Pharmaceuticals (AMRX), reported the sale of Class A common stock on 08/12/2025. The filing shows 33,436 shares were disposed in one or more transactions at a weighted average price of approximately $9.05 per share, with individual trade prices ranging from $9.05 to $9.07.
After these transactions, Boyer directly beneficially owns 256,670 shares. The Form 4 discloses no derivative transactions and includes a footnote stating the sales were executed in multiple transactions and that the reporting person will provide detailed per-price allocation upon request.
Amneal Pharmaceuticals (AMRX) filed a Form 144 disclosing a proposed sale of 169,206 common shares, with an aggregate market value of $1,568,539.00, to occur approximately on 08/13/2025 on NASDAQ through Charles Schwab Corp. The filing shows the shares were acquired by RSU vesting in March 2023 in three tranches: 87,719 on 03/12/2023, 36,197 on 03/01/2023 and 45,290 on 03/03/2023. The notice also records a sale during the past three months: Anastasios Konidaris sold 111,635 shares on 08/13/2025 for gross proceeds of $1,021,157.97. The signee represents there is no undisclosed material adverse information.
Amneal Pharmaceuticals (AMRX) submitted a Rule 144 notice reporting a proposed sale of 111,635 common shares with an aggregate market value of $1,006,947.00. The sale is planned on NASDAQ through Charles Schwab (3000 Schwab Way, Westlake, TX) with an approximate sale date of 08/13/2025. The filing shows 314,079,309 shares outstanding for the issuer.
The shares to be sold were acquired via RSU vesting on 03/01/2022 (23,916 shares) and 03/12/2022 (87,719 shares). The filer reports no securities sold in the past three months. The notice includes the standard representation that the filer does not possess undisclosed material adverse information and references trading-plan/Rule 10b5-1 considerations.
Amneal Pharmaceuticals (AMRX) Form 144 discloses a proposed sale of 33,436 Common Class A shares through Charles Schwab (3000 Schwab Way, Westlake, TX) with an aggregate market value of $304,100.00. The filing reports 314,079,309 shares outstanding and lists the approximate sale date as 08/12/2025 on NASDAQ. The shares were acquired as restricted stock awards from the issuer on 03/03/2025 (14,779 shares) and 03/04/2025 (18,657 shares) and were paid via Equity Compensation. The filer reports Nothing to Report for securities sold in the past three months and includes the standard representation that no material nonpublic information is known.
Amneal Pharmaceuticals (AMRX) Form 144 reports a proposed sale of 22,000 Class A shares through Merrill Lynch with an approximate sale date of 08/12/2025 and an aggregate market value of $198,000. The filing shows the shares were acquired on 03/03/2025 as equity compensation from Amneal Pharmaceuticals and that payment was made on the same date.
The filing lists 18,067,134 shares outstanding and indicates there were no securities sold by the person in the past three months. The filer also represents that they have no undisclosed material adverse information about the issuer.
Form 144 filing for Amneal Pharmaceuticals (AMRX) reports a proposed insider sale of 50,000 shares of common stock with an aggregate market value of $453,000. The filing lists 314,079,309 shares outstanding, and the approximate date of sale is 08/12/2025 on Nasdaq. The shares were originally acquired on 07/05/2018 as equity compensation.
The filing also discloses a recent sale of 49,140 shares on 05/16/2025 generating $370,541, and includes the standard insider representation that the seller is not aware of any undisclosed material adverse information. The notice documents compliance with Rule 144 procedures but does not provide additional operational or financial data.
Chirag K. Patel reports beneficial ownership of 22,180,421 shares of Amneal Pharmaceuticals Class A common stock, representing 7.1% of the class based on 314,079,309 shares outstanding. Of that total, Mr. Patel directly owns 857,980 shares and holds options for 24,977 and 28,044 shares; trusts he controls hold 21,269,420 shares. The filing states no transactions in the past 60 days and shows sole voting and dispositive power over the reported shares.
The filing also discloses an Omnibus Amendment to the Margin Loan Agreement and Pledge and Security Agreement dated August 6, 2025, which increases the collateral pledged to 19,000,000 shares and extends the loan maturity to April 29, 2028. The amended Pledge and Security Agreement is filed as an exhibit.